(Total Views: 573)
Posted On: 04/17/2023 5:52:16 PM
Post# of 154877
For those that don’t remember, CytoDyn hired other companies to work on the things we had already submitted. Non clinical, etc.
This was around the time we already knew Amarex botched us, per Recknor finding out the switch in dates etc.
Shortly after; CytoDyn wasn’t allowed to talk about it much, AND we already went to a different management team.
(I believe submitting these things have been section by section for a while.)
So while some can complain about informal meetings, I always took it as it’s part of the HIV BLA (AND) Amarex damage + future indication baseline.
There’s also much more details that I feel longs forgot that will help catapult our position in doing trials nicely.
…but if some basher tries to say it was Naders team etc, it was actually another entity doing the work, because we hired them and that’s why we are attracting nice talent because we are seeing progress with .0001 P-Value data.
Milestones will be met Imo, but in the meantime, we aren’t waiting, we are aligning several different approaches to being successful.
Leronlimab + HIV
Leronlimab + indications
Leronlimab long acting
Leronlimab + derivatives / 3rd party agreement
This was around the time we already knew Amarex botched us, per Recknor finding out the switch in dates etc.
Shortly after; CytoDyn wasn’t allowed to talk about it much, AND we already went to a different management team.
(I believe submitting these things have been section by section for a while.)
So while some can complain about informal meetings, I always took it as it’s part of the HIV BLA (AND) Amarex damage + future indication baseline.
There’s also much more details that I feel longs forgot that will help catapult our position in doing trials nicely.
…but if some basher tries to say it was Naders team etc, it was actually another entity doing the work, because we hired them and that’s why we are attracting nice talent because we are seeing progress with .0001 P-Value data.
Milestones will be met Imo, but in the meantime, we aren’t waiting, we are aligning several different approaches to being successful.
Leronlimab + HIV
Leronlimab + indications
Leronlimab long acting
Leronlimab + derivatives / 3rd party agreement
(8)
(0)
